Finoriq research workspace
Allarity Therapeutics, Inc. (ALLR) Company Overview
Allarity Therapeutics, Inc. develops drugs for the personalized treatment of cancer using drug-specific. Review ALLR filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
- Company
- Allarity Therapeutics, Inc. (ALLR)
- Ticker
- ALLR
- Market Cap
- $18.2M
- Latest Price
- $1.1799
- Industry
- Biotech & Pharma
Allarity Therapeutics, Inc. (ALLR) Current Valuation Metrics
Static valuation preview for Allarity Therapeutics, Inc. (ALLR). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 58.0x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -60.5% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -79.9% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 1.89x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.